TERN Terns Pharmaceuticals, Inc.
Healthcare$52.95-0.03%ClosedMarket Cap: $4.77B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.90
P/S
0.00
EV/EBITDA
-38.55
DCF Value
$5.60
FCF Yield
-1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-20.0%
ROA
-9.4%
ROIC
-10.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $0.00 | Infinity% | $-27.6M | $-23.6M | $— | — |
| FY null | $0.00 | NaN% | $-110.1M | $-96.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-27.7M | $-24.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-27.4M | $-24.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-27.4M | $-23.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-25.9M | $-21.8M | $— | — |
| FY null | $0.00 | NaN% | $-101.9M | $-88.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-24.9M | $-21.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-25.5M | $-22.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-25.4M | $-22.4M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-24.1M | $-21.0M | $-0.29 | — |
| FY null | $0.00 | NaN% | $-102.6M | $-90.2M | $— | — |